NASDAQ:CORT - Corcept Therapeutics Stock Price, Forecast & News

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its earnings results on Thursday, February, 20th. The biotechnology company reported $0.24 EPS for the quarter, hitting the Thomson Reuters' consensus estimate of $0.24. The biotechnology company had revenue of $87.90 million for the quarter, compared to analysts' expectations of $87.85 million. Corcept Therapeutics had a net margin of 30.73% and a return on equity of 30.77%. The business's revenue for the quarter was up 31.6% on a year-over-year basis. During the same period last year, the firm earned $0.18 earnings per share. View Corcept Therapeutics' Earnings History.

Corcept Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Corcept Therapeutics.

Corcept Therapeutics updated its FY 2020 After-Hours earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $355-375 million, compared to the consensus revenue estimate of $350.85 million.

3 Wall Street analysts have issued 1-year price objectives for Corcept Therapeutics' shares. Their forecasts range from $15.00 to $20.00. On average, they anticipate Corcept Therapeutics' stock price to reach $17.67 in the next twelve months. This suggests a possible upside of 30.0% from the stock's current price. View Analyst Price Targets for Corcept Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corcept Therapeutics.

Media coverage about CORT stock has been trending very negative this week, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Corcept Therapeutics earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Corcept Therapeutics.

Some companies that are related to Corcept Therapeutics include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), CA (CA), BlackRock (BLK), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), Alibaba Group (BABA), Endologix (ELGX), Energy Transfer LP Unit (ET) and Celgene (CELG).

Corcept Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (7.01%), Renaissance Technologies LLC (6.80%), State Street Corp (2.65%), LSV Asset Management (1.50%), Geode Capital Management LLC (1.25%) and Parallel Advisors LLC (1.23%). Company insiders that own Corcept Therapeutics stock include G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Renee D Gala, Robert S Fishman and Sean Maduck. View Institutional Ownership Trends for Corcept Therapeutics.

CORT stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Marshall Wace LLP, PNC Financial Services Group Inc., AJO LP, State of New Jersey Common Pension Fund D, Bank of America Corp DE, AQR Capital Management LLC and AlphaCrest Capital Management LLC. View Insider Buying and Selling for Corcept Therapeutics.

CORT stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, LSV Asset Management, Man Group plc, Mackay Shields LLC, First Trust Advisors LP, Goldman Sachs Group Inc., California Public Employees Retirement System and Parallel Advisors LLC. Company insiders that have bought Corcept Therapeutics stock in the last two years include G Leonard Baker Jr and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CORT stock can currently be purchased for approximately $13.59.

Corcept Therapeutics has a market capitalization of $1.55 billion and generates $306.49 million in revenue each year. The biotechnology company earns $75.41 million in net income (profit) each year or $0.77 on an earnings per share basis. Corcept Therapeutics employs 166 workers across the globe.View Additional Information About Corcept Therapeutics.

The official website for Corcept Therapeutics is http://www.corcept.com/.

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]